Paracetamol, NSAIDs and other analgesics
The arachidonic acid cascade and the two cyclo-oxygenase isoforms, how non-steroidal anti-inflammatory drugs produce both their benefits and their predictable harms, the pharmacology and toxicity mechanism of paracetamol, and the other agents used for pain: ketamine, nitrous oxide, antineuropathic drugs and the adjuvants.
By the end of this page you should be able to
- Describe the arachidonic acid cascade and the roles of the two cyclo-oxygenase isoforms.
- Explain the analgesic, antipyretic and anti-inflammatory actions of non-steroidal anti-inflammatory drugs.
- Account for the gastrointestinal, renal, cardiovascular, respiratory and haematological adverse effects in mechanistic terms.
- Describe the pharmacology of paracetamol and the mechanism of its hepatotoxicity and antidote.
- Describe the mechanisms of ketamine, nitrous oxide and the drugs used for neuropathic pain.
- Explain the principles of multimodal analgesia.
The cascade
Tissue injury activates phospholipase A2, which releases arachidonic acid from membrane phospholipid (the step that corticosteroids suppress). Arachidonic acid is then metabolised by two routes: cyclo-oxygenase to the prostaglandins, prostacyclin and thromboxane, and lipoxygenase to the leukotrienes.
Cyclo-oxygenase 1 is constitutive and housekeeping: thromboxane A2 in platelets (aggregation and vasoconstriction), prostaglandins maintaining gastric mucus and bicarbonate and mucosal blood flow, prostaglandins dilating the renal afferent arteriole, and prostaglandins maintaining ductal patency in the fetus.
Cyclo-oxygenase 2 is largely inducible by cytokines at sites of inflammation, although it is constitutive in kidney, brain and endothelium. Its products sensitise nociceptors to bradykinin and histamine (prostaglandins cause hyperalgesia rather than pain directly), cause vasodilatation and increased permeability, and raise the hypothalamic set point to produce fever. Endothelial prostacyclin, which opposes platelet aggregation, is also largely a cyclo-oxygenase 2 product, which is the basis of the cardiovascular risk of selective inhibition.
Non-steroidal anti-inflammatory drugs
- Mechanism: inhibition of cyclo-oxygenase, so less prostaglandin at the inflamed site. Hence analgesia (especially for inflammatory, bone and renal colic pain), anti-inflammatory and antipyretic effects. Aspirin is unique in irreversibly acetylating the enzyme, which is why its platelet effect lasts the life of the platelet.
- Classification by selectivity: non-selective (ibuprofen, naproxen, diclofenac, indomethacin, ketorolac), relatively cyclo-oxygenase 2 selective (meloxicam, celecoxib, parecoxib), and aspirin as an irreversible non-selective inhibitor.
- Kinetics: well absorbed orally, highly protein bound (so displacement interactions and greater free fraction in hypoalbuminaemia), mostly hepatically metabolised, weak acids that concentrate in inflamed acidic tissue and in the renal tubule.
- Gastrointestinal harm follows loss of cyclo-oxygenase 1-dependent mucosal defence, plus local acid trapping of the drug: dyspepsia, erosion, ulcer, bleeding and perforation. Selective agents and co-prescribed proton pump inhibitors reduce but do not remove it.
- Renal harm follows loss of afferent arteriolar dilatation, which matters when glomerular filtration depends on prostaglandins: hypovolaemia, hypotension, sepsis, cirrhosis, heart failure, renal artery stenosis and old age. Combined with a renin system blocker and a diuretic (the "triple whammy") it causes acute kidney injury. Also sodium and water retention, hyperkalaemia, hypertension, interstitial nephritis and papillary necrosis with chronic use.
- Cardiovascular harm: inhibiting endothelial prostacyclin while leaving platelet thromboxane relatively intact tips the balance towards thrombosis, so selective agents and high-dose diclofenac increase myocardial infarction and stroke risk; all of them raise blood pressure and worsen heart failure.
- Respiratory: in aspirin-exacerbated respiratory disease, blocking cyclo-oxygenase shunts substrate down the lipoxygenase route, raising leukotrienes and causing bronchospasm and rhinitis; this is a pharmacological reaction, not an allergy, and it is cross-reactive across the class.
- Other: impaired platelet function and bleeding, fluid retention masking fever and infection signs, impaired bone and wound healing, aseptic meningitis, and avoidance in the third trimester because of ductal closure and renal effects in the fetus.
Paracetamol
Mechanism remains incompletely settled, which is a reasonable thing to say in a viva. It is a weak peripheral cyclo-oxygenase inhibitor but acts mainly centrally: inhibition of a cyclo-oxygenase variant in the central nervous system in a reducing environment, an active metabolite acting on cannabinoid and vanilloid systems, and effects on descending serotonergic inhibition are all implicated. The clinically important consequence is that it is an analgesic and antipyretic with little anti-inflammatory effect, no antiplatelet effect, no gastric or renal prostaglandin penalty at therapeutic exposure, and safety in pregnancy and in asthma.
Kinetics: rapid and near-complete oral absorption with a modest first-pass effect; small volume of distribution; low protein binding; a short half-life; hepatic metabolism, mostly by glucuronidation and sulfation to inactive conjugates.
Toxicity mechanism: a small fraction is oxidised by CYP2E1 to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is immediately conjugated by glutathione. In excessive exposure the conjugating pathways saturate, more substrate is diverted through CYP2E1, and glutathione is consumed; unconjugated NAPQI then binds cysteine groups on hepatocyte proteins, causing oxidative injury, mitochondrial failure and centrilobular (zone 3) necrosis, where CYP2E1 activity is highest and oxygen tension lowest. Chronic alcohol and enzyme inducers raise NAPQI production, while malnutrition, fasting and chronic illness lower glutathione reserve, so the same exposure carries different risk in different patients.
Antidote principle: acetylcysteine supplies cysteine for glutathione resynthesis, acts as a glutathione substitute and a direct antioxidant, and improves microcirculatory flow. It works best when given before injury is established, which is why treatment is started on risk assessment rather than waiting for abnormal liver tests. Risk assessment, timing and regimens vary between guidelines, so follow your local or national poisons guideline and the Australian Medicines Handbook. The infusion itself can cause a non-immune histaminoid reaction, which responds to slowing the infusion and antihistamine rather than to abandoning treatment.
The other analgesics
- Ketamine: a non-competitive NMDA receptor antagonist producing dissociative analgesia with preserved airway reflexes and respiratory drive, and sympathomimetic effects through catecholamine reuptake inhibition (so it tends to raise heart rate and pressure, unless catecholamine stores are exhausted). At low doses it is a useful analgesic adjunct that reduces opioid requirement and attenuates central sensitisation and opioid tolerance. Adverse effects: emergence phenomena, hypersalivation, nausea, raised intraocular pressure, laryngospasm in children, and a transient rise in blood pressure; it is also a bronchodilator.
- Nitrous oxide: analgesic and anxiolytic, acting partly through NMDA antagonism and partly through endogenous opioid and descending noradrenergic pathways. Very low blood solubility gives rapid onset and offset. It diffuses into closed gas spaces, so it is avoided in pneumothorax, bowel obstruction, middle ear surgery and after recent intraocular gas; prolonged or repeated use inhibits methionine synthase and so interferes with vitamin B12-dependent metabolism.
- Antineuropathic agents: gabapentinoids bind the alpha-2-delta subunit of presynaptic voltage-gated calcium channels, reducing excitatory transmitter release (renally cleared, sedating, and misused); tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors enhance descending inhibition; carbamazepine blocks sodium channels and is the agent of choice for trigeminal neuralgia; lignocaine infusions and topical agents act on sodium channels.
- Adjuvants with a mechanism worth knowing: corticosteroids (phospholipase A2 inhibition and reduced oedema), antispasmodics for colic, triptans (5-HT1B and 1D agonists causing cranial vasoconstriction and reduced neuropeptide release) and antiemetic dopamine antagonists that are independently effective in migraine.
- Multimodal analgesia is the practical point: combining drugs that act at different points (nociceptor, peripheral nerve, dorsal horn, descending pathway, cortex) with regional techniques gives better analgesia with fewer dose-related adverse effects than escalating any single agent. Paracetamol plus a non-steroidal agent is better than either alone, and both reduce opioid requirement.
Making the answer flow
- Draw the cascade first; then every benefit and every adverse effect of a non-steroidal drug can be derived from the prostaglandin lost.
- State clearly that paracetamol is not an anti-inflammatory drug and explain the central mechanism as uncertain but probably multiple.
- Describe paracetamol toxicity as a saturation and glutathione depletion problem, and the antidote as glutathione replenishment.
- Finish analgesia questions with multimodal reasoning rather than a single drug.
Where marks are lost
- Saying prostaglandins cause pain directly; they sensitise nociceptors.
- Claiming selective cyclo-oxygenase 2 inhibitors are free of renal risk; the enzyme is constitutive in the kidney.
- Calling aspirin-exacerbated respiratory disease an allergy.
- Saying the hepatotoxic metabolite is paracetamol itself rather than NAPQI, or that acetylcysteine binds paracetamol.
- Forgetting that ketamine raises catecholamine levels but is a direct negative inotrope, so it can drop pressure in a catecholamine-depleted patient.
Where this meets intensive care
- NSAIDs inhibit prostaglandins that maintain renal blood flow when it is threatened, so they are a common contributor to acute kidney injury in hypovolaemic ICU patients.
- Ketamine at subanaesthetic levels is an NMDA antagonist that reduces opioid requirement and can help in opioid tolerance.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe the arachidonic acid cascade and the differences between the cyclo-oxygenase isoforms.
Show answer
- Phospholipase A2 releases arachidonic acid from membrane phospholipid; corticosteroids inhibit this.
- Cyclo-oxygenase route to prostaglandins, prostacyclin and thromboxane; lipoxygenase route to leukotrienes.
- Cyclo-oxygenase 1: constitutive; platelet thromboxane, gastric mucosal protection, renal afferent dilatation.
- Cyclo-oxygenase 2: mainly inducible at inflamed sites, but constitutive in kidney, brain and endothelium where it makes prostacyclin.
- 2.
Explain the adverse effects of non-steroidal anti-inflammatory drugs in mechanistic terms.
Show answer
- Gastrointestinal: loss of mucosal prostaglandins plus local acid trapping, causing erosion, ulcer and bleeding.
- Renal: loss of afferent arteriolar dilatation in prostaglandin-dependent states; sodium retention, hyperkalaemia, interstitial nephritis.
- Cardiovascular: reduced endothelial prostacyclin relative to platelet thromboxane; hypertension and fluid retention worsening heart failure.
- Respiratory: substrate shunting to leukotrienes causing bronchospasm in susceptible patients.
- Haematological: impaired platelet aggregation and bleeding; irreversible with aspirin.
- 3.
Why is aspirin different from the other drugs in its class?
Show answer
- Irreversible acetylation of cyclo-oxygenase rather than reversible competitive inhibition.
- Platelets cannot synthesise new enzyme, so the antiplatelet effect lasts the platelet lifespan of about 7 to 10 days.
- Low doses selectively suppress platelet thromboxane while sparing endothelial prostacyclin.
- Also causes a mixed respiratory alkalosis then metabolic acidosis in toxicity, and is associated with Reye syndrome in children.
- 4.
What is the mechanism of action of paracetamol, and why is it not an anti-inflammatory drug?
Show answer
- Mainly central: inhibition of a central cyclo-oxygenase variant in a reducing environment, active metabolite effects on cannabinoid and vanilloid systems, enhanced descending serotonergic inhibition.
- Only weak peripheral cyclo-oxygenase inhibition, and that inhibition is reduced by the high peroxide concentration at inflamed sites.
- Hence analgesia and antipyresis without appreciable anti-inflammatory or antiplatelet effect.
- Consequently safe in asthma, pregnancy and peptic ulcer disease at therapeutic exposure.
- 5.
Describe the metabolism of paracetamol and the mechanism of hepatotoxicity.
Show answer
- Mostly glucuronidation and sulfation to inactive conjugates; a small fraction oxidised by CYP2E1 to NAPQI.
- NAPQI is normally conjugated by glutathione.
- In excessive exposure the conjugating pathways saturate and glutathione is depleted; free NAPQI binds hepatocyte proteins causing oxidative and mitochondrial injury.
- Centrilobular zone 3 necrosis, where CYP2E1 is concentrated and oxygen tension is lowest.
- Risk is modified by enzyme inducers, chronic alcohol, fasting and malnutrition.
- 6.
How does acetylcysteine work?
Show answer
- Provides cysteine for glutathione resynthesis, restoring NAPQI conjugation.
- Acts as a glutathione substitute and a free radical scavenger, and improves microcirculatory oxygen delivery.
- Most effective before injury is established, so it is started on risk assessment rather than on abnormal liver tests.
- Non-immune histaminoid reactions are common and are managed by slowing the infusion with antihistamine, not by stopping treatment.
- 7.
Describe the pharmacology of ketamine.
Show answer
- Non-competitive NMDA receptor antagonist; also effects at opioid, muscarinic and monoamine sites.
- Dissociative state with analgesia, amnesia and preserved airway reflexes and respiratory drive.
- Indirect sympathomimetic by catecholamine reuptake inhibition, so pressure and rate usually rise; a direct negative inotrope, so pressure may fall when catecholamines are depleted.
- Bronchodilator; raises salivation; emergence phenomena; high lipid solubility gives rapid onset and redistribution offset.
- Low-dose use as an opioid-sparing analgesic that attenuates central sensitisation.
- 8.
What is multimodal analgesia and why does it work?
Show answer
- Combining agents and techniques acting at different points in the pain pathway: nociceptor, peripheral nerve, dorsal horn, descending modulation, cortex.
- Additive or synergistic analgesia with lower exposure to each drug, so fewer dose-related adverse effects.
- Example combination: paracetamol, a non-steroidal agent if not contraindicated, a regional block, and opioid as rescue.
- Also reduces opioid requirement, which lowers respiratory depression, nausea and tolerance.
Practise this week
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 12 in the other subjects
- Physiology: Haemorrhage, posture and exercise
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.